Curious Biosimilar Issues: More Workload, But Fewer US FDA Staff Needed
New Biosimilar User Fees Are Announced By FDA
The US FDA’s capacity planning formula indicates a smaller biosimilar program than a year ago, but says supplement, meeting and other work continue to increase.
